227 results on '"Stringer, Andrea M"'
Search Results
2. Effects of coronavirus disease 19 on the gastrointestinal tract and the potential impact on gastrointestinal toxicities during cancer treatment
3. Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo
4. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery
5. New therapeutic strategies for combatting gastrointestinal toxicity
6. Editorial: New innovations in therapeutic targets for gastrointestinal toxicity: exploring targets beyond the intestine
7. Editorial: Knowledge of gastrointestinal toxicity mechanisms is paving the way for improved assessment and management of patient supportive care
8. Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets
9. Vitamin D is a potential treatment for the management of gastrointestinal mucositis.
10. Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity
11. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues
12. Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding
13. The effect of free and encapsulated cisplatin into long-circulating and pH-sensitive liposomes on IEC-6 cells during wound healing in the presence of host–microbiota
14. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model
15. Emerging evidence on the pathobiology of mucositis
16. Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract
17. Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis
18. The role of oral flora in the development of chemotherapy-induced oral mucositis
19. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases
20. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
21. Irinotecan-induced mucositis is associated with changes in intestinal mucins
22. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
23. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
24. Therapeutic Potential of a Novel Vitamin D 3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding.
25. effect of free and encapsulated cisplatin into long-circulating and pH-sensitive liposomes on IEC-6 cells during wound healing in the presence of host–microbiota.
26. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat
27. Maintaining anorectal function in patients with rectal cancer using biofeedback training
28. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
29. Highlight article: Current evidence for vitamin D in intestinal function and disease
30. Animal models of mucositis:critical tools for advancing pathobiological understanding and identifying therapeutic targets
31. Current evidence for vitamin D in intestinal function and disease
32. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis
33. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.
34. Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis
35. Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity
36. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.
37. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues
38. Anti-Inflammatory Cytokines: Important Immunoregulatory Factors Contributing to Chemotherapy-Induced Gastrointestinal Mucositis
39. Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis
40. The role of oral flora in the development of chemotherapy-induced oral mucositis
41. Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors
42. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea
43. Selection of Housekeeping Genes for Gene Expression Studies in a Rat Model of Irinotecan-Induced Mucositis
44. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat
45. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis
46. Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis
47. Chemotherapy-induced diarrhoea
48. Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
49. Irinotecan-induced mucositis is associated with changes in intestinal mucins
50. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.